PE20050679A1 - Compuestos de pirrolotriazina como inhibidores de la cinasa - Google Patents
Compuestos de pirrolotriazina como inhibidores de la cinasaInfo
- Publication number
- PE20050679A1 PE20050679A1 PE2005000015A PE2005000015A PE20050679A1 PE 20050679 A1 PE20050679 A1 PE 20050679A1 PE 2005000015 A PE2005000015 A PE 2005000015A PE 2005000015 A PE2005000015 A PE 2005000015A PE 20050679 A1 PE20050679 A1 PE 20050679A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- kinase inhibitors
- compounds
- triazin
- heterocyclyl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- JPKXJWBKGYESKN-UHFFFAOYSA-N 5-[(4-aminopiperidin-1-yl)methyl]-n-phenylpyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound C1CC(N)CCN1CC1=C2C(NC=3C=CC=CC=3)=NC=NN2C=C1 JPKXJWBKGYESKN-UHFFFAOYSA-N 0.000 abstract 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I DONDE R1 ES CICLOALQUILO, ARILO, HETEROCICLILO, ENTRE OTROS; R2 ES ARILO, HETEROARILO, HETEROCICLILO, ENTRE OTROS; R3 ES H, ALQUILO SUSTITUIDO O NO; X ES ENLACE DIRECTO, NH, O; Y ES ENLACE DIRECTO ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-[(4-AMINO-1-PIPERIDINIL)METIL]-N-FENILPIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y N-[(3S,4R)-4-AMINO-1-({4-[(3-METOXIFENIL)AMINO]PIRROLO[2,1-f][1,2,4]TRIAZIN-5-IL}METIL)PIPERIDIN-3-IL]METANSULFONAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES COMO AGENTES ANTIPROLIFERATIVOS E INHIBIDORES DE LA ACTIVIDAD TIROSINA CINASA DE LOS RECEPTORES DEL FACTOR DE CRECIMIENTO TALES COMO HER1, HER2, HER3 Y HER4
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53333503P | 2003-12-29 | 2003-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050679A1 true PE20050679A1 (es) | 2005-09-25 |
Family
ID=34748887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000015A PE20050679A1 (es) | 2003-12-29 | 2005-01-03 | Compuestos de pirrolotriazina como inhibidores de la cinasa |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7141571B2 (es) |
| EP (2) | EP2058314A1 (es) |
| JP (1) | JP4740878B2 (es) |
| KR (1) | KR100839716B1 (es) |
| CN (1) | CN1922182B (es) |
| AR (1) | AR047076A1 (es) |
| AT (1) | ATE443706T1 (es) |
| AU (1) | AU2004312413C1 (es) |
| BR (1) | BRPI0418231A (es) |
| CA (1) | CA2552107C (es) |
| CL (1) | CL2009001492A1 (es) |
| CY (1) | CY1109662T1 (es) |
| DE (1) | DE602004023324D1 (es) |
| DK (1) | DK1699797T3 (es) |
| ES (1) | ES2331842T3 (es) |
| GE (1) | GEP20105081B (es) |
| HR (1) | HRP20090601T1 (es) |
| IL (1) | IL176450A0 (es) |
| MX (1) | MXPA06007038A (es) |
| MY (1) | MY145634A (es) |
| NO (1) | NO20062763L (es) |
| NZ (2) | NZ573544A (es) |
| PE (1) | PE20050679A1 (es) |
| PL (1) | PL1699797T3 (es) |
| PT (1) | PT1699797E (es) |
| RU (1) | RU2373209C2 (es) |
| SI (1) | SI1699797T1 (es) |
| TW (1) | TWI332840B (es) |
| UA (1) | UA89038C2 (es) |
| WO (1) | WO2005066176A1 (es) |
| ZA (1) | ZA200605160B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| AU2003231034B2 (en) * | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| ES2319462T3 (es) | 2005-03-28 | 2009-05-07 | Bristol-Myers Squibb Company | Inhibidores competitivos de atp cinasas. |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| JP5193876B2 (ja) * | 2005-12-02 | 2013-05-08 | バイエル・ヘルスケア・エルエルシー | オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体 |
| US8063208B2 (en) * | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| WO2008057863A1 (en) * | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound |
| EP2115130B1 (en) | 2007-02-08 | 2011-08-03 | Codexis, Inc. | Ketoreductases and uses thereof |
| US20090076034A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched bms-690514 |
| CA2704125A1 (en) * | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| JP2010209058A (ja) * | 2008-09-29 | 2010-09-24 | Sumitomo Chemical Co Ltd | １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法 |
| JP5592890B2 (ja) * | 2008-10-08 | 2014-09-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| WO2010071885A1 (en) | 2008-12-19 | 2010-06-24 | Cephalon, Inc. | Pyrrolotriazines as alk and jak2 inhibitors |
| CA2750047A1 (en) | 2009-01-21 | 2010-07-29 | Basilea Pharmaceutica Ag | Novel bicyclic antibiotics |
| JPWO2011013656A1 (ja) * | 2009-07-28 | 2013-01-07 | 宇部興産株式会社 | ピロロ［２，３−ｄ］ピリミジン誘導体 |
| CA2788355C (en) | 2010-02-18 | 2018-03-06 | Devi Reddy Gohimukkula | Phenyl-heteroaryl derivatives and methods of use thereof |
| EP2589592B1 (en) | 2010-06-30 | 2018-08-22 | FUJIFILM Corporation | Novel nicotinamide derivatives or salts thereof |
| CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
| DE102011119127A1 (de) * | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| JP6473146B2 (ja) | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピロロトリアジンキナーゼ阻害剤 |
| SI3466955T1 (sl) * | 2014-01-13 | 2021-05-31 | Aurigene Discovery Technologies Limited | Postopek za pripravo derivatov oksazolo(4,5-B)piridina in tiazolo(4,5-B)piridina kot inhibitorjev IRAK4 za zdravljenje raka |
| CN110044998B (zh) * | 2014-05-12 | 2021-12-14 | 奎斯特诊断投资公司 | 通过质谱法定量他莫昔芬及其代谢物 |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| US12030897B2 (en) | 2018-05-08 | 2024-07-09 | Medshine Discovery Inc. | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof |
| WO2021088987A1 (zh) * | 2019-11-08 | 2021-05-14 | 南京明德新药研发有限公司 | 作为选择性her2抑制剂的盐型、晶型及其应用 |
| WO2022046631A1 (en) | 2020-08-24 | 2022-03-03 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| US20240132521A1 (en) * | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
| WO2025178975A1 (en) * | 2024-02-20 | 2025-08-28 | Iambic Therapeutics, Inc. | Doses and regimens of her2 inhibitors |
| CN120271495B (zh) * | 2025-06-12 | 2025-09-19 | 成都道合尔医药技术有限公司 | 一种(3r,4r)-n-pg-4-氨基-3-甲基哌啶的合成方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2127274C1 (ru) * | 1992-09-25 | 1999-03-10 | Эли Лилли Энд Компани | СПОСОБ ПОЛУЧЕНИЯ 5-ЗАМЕЩЕННЫХ ПИРРОЛО (2,3-α)ПИРИМИДИНОВ |
| CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| KR100666514B1 (ko) * | 1999-05-21 | 2007-02-28 | 브리스톨-마이어즈 스퀴브 컴페니 | 키나제의 피롤로트리아진 저해제 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| GEP20063915B (en) | 2000-11-17 | 2006-09-11 | Bristol Myers Squibb Co | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS |
| TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| TW200306841A (en) * | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| US6894066B2 (en) | 2002-05-09 | 2005-05-17 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| TWI272271B (en) | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP1543009A4 (en) | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazine KINASE INHIBITORS |
| TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| US7064203B2 (en) * | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7102003B2 (en) * | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
-
2004
- 2004-12-09 MY MYPI20045093A patent/MY145634A/en unknown
- 2004-12-22 TW TW093140035A patent/TWI332840B/zh not_active IP Right Cessation
- 2004-12-22 US US11/019,901 patent/US7141571B2/en not_active Expired - Lifetime
- 2004-12-23 PL PL04815269T patent/PL1699797T3/pl unknown
- 2004-12-23 RU RU2006127396/04A patent/RU2373209C2/ru not_active IP Right Cessation
- 2004-12-23 NZ NZ573544A patent/NZ573544A/en unknown
- 2004-12-23 CN CN2004800421984A patent/CN1922182B/zh not_active Expired - Fee Related
- 2004-12-23 CA CA2552107A patent/CA2552107C/en not_active Expired - Fee Related
- 2004-12-23 AT AT04815269T patent/ATE443706T1/de active
- 2004-12-23 KR KR1020067012936A patent/KR100839716B1/ko not_active Expired - Fee Related
- 2004-12-23 PT PT04815269T patent/PT1699797E/pt unknown
- 2004-12-23 SI SI200431286T patent/SI1699797T1/sl unknown
- 2004-12-23 EP EP09153694A patent/EP2058314A1/en not_active Withdrawn
- 2004-12-23 WO PCT/US2004/043169 patent/WO2005066176A1/en not_active Ceased
- 2004-12-23 GE GEAP20049544A patent/GEP20105081B/en unknown
- 2004-12-23 ES ES04815269T patent/ES2331842T3/es not_active Expired - Lifetime
- 2004-12-23 NZ NZ548070A patent/NZ548070A/en unknown
- 2004-12-23 DK DK04815269T patent/DK1699797T3/da active
- 2004-12-23 UA UAA200608400A patent/UA89038C2/ru unknown
- 2004-12-23 JP JP2006547328A patent/JP4740878B2/ja not_active Expired - Fee Related
- 2004-12-23 EP EP04815269A patent/EP1699797B1/en not_active Expired - Lifetime
- 2004-12-23 DE DE602004023324T patent/DE602004023324D1/de not_active Expired - Lifetime
- 2004-12-23 HR HR20090601T patent/HRP20090601T1/hr unknown
- 2004-12-23 MX MXPA06007038A patent/MXPA06007038A/es active IP Right Grant
- 2004-12-23 AU AU2004312413A patent/AU2004312413C1/en not_active Ceased
- 2004-12-23 BR BRPI0418231-6A patent/BRPI0418231A/pt not_active IP Right Cessation
- 2004-12-29 AR ARP040104947A patent/AR047076A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 PE PE2005000015A patent/PE20050679A1/es not_active Application Discontinuation
-
2006
- 2006-06-13 NO NO20062763A patent/NO20062763L/no not_active Application Discontinuation
- 2006-06-20 IL IL176450A patent/IL176450A0/en unknown
- 2006-06-22 ZA ZA200605160A patent/ZA200605160B/en unknown
- 2006-06-26 US US11/426,479 patent/US7297695B2/en not_active Expired - Lifetime
-
2008
- 2008-09-24 US US11/869,910 patent/US7846931B2/en not_active Expired - Lifetime
-
2009
- 2009-06-26 CL CL2009001492A patent/CL2009001492A1/es unknown
- 2009-12-21 CY CY20091101326T patent/CY1109662T1/el unknown
-
2010
- 2010-10-25 US US12/911,299 patent/US20110039838A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050679A1 (es) | Compuestos de pirrolotriazina como inhibidores de la cinasa | |
| PE20040934A1 (es) | Derivados de pirimidina como inhibidores selectivos de tirosina quinasas | |
| PE20060664A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| PE20040805A1 (es) | Indazolilpirrolotriazinas c-6 modificadas | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| PE20050232A1 (es) | Metodo y composiciones para tratar la artritis reumatoide | |
| PE20040647A1 (es) | Inhibidores de cinasas de tirosina | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| PE20110411A1 (es) | Imidazopiridazinacarbonitrilos como inhibidores de quinasa | |
| PE20090279A1 (es) | Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2 | |
| PE20010760A1 (es) | DERIVADOS DE DIHIDROPIRIMIDO[4,5]PIRIMIDINONA ALQUILAMINO SUSTITUIDOS COMO INHIBIDORES DE QUINASAS p38 | |
| PE20030866A1 (es) | Inhibidores de tirosina-quinasa para el tratamiento de procesos inflamatorios | |
| PE20050020A1 (es) | DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20050087A1 (es) | Derivados de 2-oxodihidropiridina n-sustituidos | |
| PT846686E (pt) | Derivados de 1-fenil-pirazole e suas utilizacoes como agentes parasiticidas | |
| PE20030940A1 (es) | Derivados de piridina y pirimidina | |
| CO5580778A2 (es) | Derivados de lactama como antagonistas para receptores 11cby humanos | |
| PE20091849A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| PE20080139A1 (es) | Compuestos de pirrolotriazina anilina como inhibidores de cinasa | |
| DE60012223D1 (de) | Harnstoffderivate wirksam als muscarinrezeptor-antagonisten | |
| EA200100731A1 (ru) | Фенилфенантридины с ингибирующей фдэ-4 активностью | |
| PE20110944A1 (es) | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |